We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Promethean | LSE:PTH | London | Ordinary Share | GB00B08H5G38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.125 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:2576U
PPL Therapeutics PLC
15 January 2004
Date: Embargoed until 07.00 am, Thursday 15 January 2004
Contact: Chris Greig, Chairman
Lindsay Dunsmuir, Chief Financial Officer
PPL Therapeutics plc
Telephone: 0131 440 4777
Alistair Mackinnon-Musson
Philip Dennis
Hudson Sandler
Telephone: 020 7796 4133
Email: ppl@hspr.co.uk
PPL Therapeutics plc ("PPL")
PPL Therapeutics plc ("PPL")
Disposal, by public auction, of Laboratory Equipment
PPL announces that, on 14 January 2004, it held a public auction to sell certain
items of laboratory equipment from its research facility in the UK (the "
Laboratory Equipment"). The aggregate gross proceeds before selling expenses
receivable by PPL in respect of the auction is #192,000. The proceeds will be
received in cash prior to 31 January 2004.
PPL will continue to provide further updates to shareholders at the appropriate
time.
- ENDS -
This information is provided by RNS
The company news service from the London Stock Exchange
END
DISGUUQGGUPCGRC
1 Year Promethean Chart |
1 Month Promethean Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
